Covestor Ltd Has $118,000 Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Covestor Ltd boosted its holdings in Progyny, Inc. (NASDAQ:PGNY) by 69.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,868 shares of the company’s stock after purchasing an additional 2,814 shares during the period. Covestor Ltd’s holdings in Progyny were worth $118,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Progyny by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company’s stock valued at $149,939,000 after buying an additional 48,271 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Progyny by 47.5% in the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock valued at $63,414,000 after acquiring an additional 1,183,558 shares in the last quarter. State Street Corp lifted its position in shares of Progyny by 4.5% in the 3rd quarter. State Street Corp now owns 3,113,654 shares of the company’s stock worth $52,185,000 after acquiring an additional 134,861 shares during the period. River Road Asset Management LLC acquired a new stake in shares of Progyny during the 4th quarter worth approximately $25,529,000. Finally, Fort Washington Investment Advisors Inc. OH increased its position in shares of Progyny by 90.1% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after purchasing an additional 695,740 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Bank of America raised their target price on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. BTIG Research upgraded shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Monday, March 31st. JPMorgan Chase & Co. upped their target price on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Finally, Canaccord Genuity Group raised their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, February 28th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Progyny presently has a consensus rating of “Hold” and an average target price of $23.64.

Progyny Price Performance

PGNY stock opened at $22.34 on Friday. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 38.52, a P/E/G ratio of 2.39 and a beta of 1.33. The business has a fifty day moving average price of $22.01 and a 200 day moving average price of $18.68. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $34.92.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.